Document:

<PAGE> 1

            Unaudited Pro Forma Condensed Combined Balance Sheet
                            September 30, 2000
                          (In thousands of Euros)

<TABLE>
<CAPTION>

                                                                                   Pro Forma
                                                                                   Combined
                                                                                      U.S.
                     ICHOR                                                          Dollars
                  Corporation     Hippocampe SA      Pro Forma      Pro Forma    (Information
                   Historical      Historical       Adjustments      Combined        Only)
                  -----------     -------------     -----------     ---------    ------------
<S>               <C>             <C>               <C>             <C>          <C>

    ASSETS

Current Assets
  Cash and
   investments    E    2,395      E      190        E   (2,476)     E     109       $      96
  Accounts
   receivable, net        26              76                 -            102              89
  Note receivable        685               -                 -            685             600
  Other assets             -             119                 -            119             104
                  ----------      ----------        ----------      ---------       ---------
    Total current
     assets            3,106             385            (2,476)         1,015             889

  Patents and
   Other                   -              71                 -             71              62
                  ----------      ----------        ----------      ---------       ---------

                  E    3,106      E      456        E   (2,476)     E   1,086       $     951
                  ==========      ==========        ==========      =========       =========

    LIABILITIES AND SHAREHOLDERS' EQUITY

Current Liabilities
  Accounts payable
   and other
   liabilities    E        1      E      249        E        -      E     250       $     219
  Note payable             -             432                 -            432             379
                  ----------      ----------        ----------      ---------       ---------

    Total current
     liabilities           1             681                 -            682             598

Payable to
 Shareholders              -             242                 -            242             212

Shareholders' Equity
  Preferred stock      6,136               -            (6,136)             -               -
  Common stock         6,619             119            (4,816)         1,922           1,683
  Retained deficit    (9,569)           (586)            8,395         (1,760)         (1,542)
  Treasury stock         (81)              -                81              -               -
                  ----------      ----------        ----------      ---------       ---------
                       3,105            (467)           (2,476)           162             141
                  ----------      ----------        ----------      ---------       ---------
                  E    3,106      E      456        E   (2,476)     E   1,086       $     951
                  ==========      ==========        ==========      =========       =========

</TABLE>

 See Notes to Unaudited Pro Forma Condensed Combined Financial Statements.

<PAGE> 2

      Unaudited Pro Forma Condensed Combined Statement of Operations
                   For the Year Ended December 31, 1999
                 (In thousands of Euros, except per share)

<TABLE>
<CAPTION>

                       Corporation      Hippocampe SA      Pro Forma      Pro Forma
                        Historical        Historical      Adjustments      Combined
                       -----------      -------------     -----------     ---------
<S>                    <C>              <C>               <C>             <C>

Revenues
  Interest              E      143        E        -      E         -     E     143
  Other                         28                47                -            75
                        ----------        ----------      -----------     ---------
                               171                47                -           218

Costs and expenses

  General and
   administrative              350                49                -           399
  Research and
   development                   -                97                -            97
  Interest                     180                 -                -           180
  Equity in loss
   of unconsolidated
   subsidiary                   83                 -                -            83
                        ----------        ----------      -----------     ---------
                               613               146                -           759
                        ----------        ----------      -----------     ---------
    Net loss            E     (442)       E      (99)     E         -     E    (541)
                        ==========        ==========      ===========     =========

Basic and
 diluted loss
 per common
 share                  E    (0.13)       E   (12.64)                     E   (0.01)
                        ==========        ==========                      =========

Weighted
 average number
 of shares
 outstanding             4,910,386             7,820                     43,486,698
                        ==========        ==========                    ===========

</TABLE>

 See Notes to Unaudited Pro Forma Condensed Combined Financial Statements.

<PAGE> 3

      Unaudited Pro Forma Condensed Combined Statement of Operations
               For the Nine Months Ended September 30, 2000
                 (In thousands of Euros, except per share)

<TABLE>
<CAPTION>

                                                                                   Pro Forma
                                                                                   Combined
                                                                                      U.S.
                  ICHOR                                                            Dollars
               Corporation      Hippocampe SA     Pro Forma     Pro Forma        (Information
                Historical       Historical      Adjustments     Combined            Only)
               -----------      -------------    -----------    ---------        ------------
<S>            <C>              <C>              <C>            <C>              <C>

Revenues
  Interest      E      107       E         10     E        -    E     117        $       103
  Gain on
   disposal
   of an
   unconsolidated
   subsidiary          316                  -              -          316                277
  Other                  6                  -              -            6                  5
                ----------       ------------     ----------    ---------        -----------
                       429                 10              -          439                385

Costs and expenses
  General and
   administrative      292                 72              -          364                319
  Research and
   development           -                148              -          148                130
  Equity in loss of
   unconsolidated
   subsidiary           65                  -              -           65                 57
                ----------       ------------     ----------    ---------        -----------
                       357                220              -          577                506
                ----------       ------------     ----------    ---------        -----------
    Net income
     (loss)     E       72       E       (210)    E        -    E    (138)       $      (121)
                ==========       ============     ==========    =========        ===========

Basic and diluted
 loss per common
 share          E    (0.03)      E     (26.85)                  E   (0.00)       $     (0.00)
                ==========       ============                   =========        ===========

Weighted average
 number of shares
 outstanding     4,918,770              7,820                  43,495,082         43,495,082
                ==========       ============                  ==========         ==========

</TABLE>

 See Notes to Unaudited Pro Forma Condensed Combined Financial Statements.

<PAGE> 4

               NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED
                          FINANCIAL STATEMENTS

(1)  ICHOR Corporation (a United States company) and Hippocampe SA (a
     French company) plan to combine their operations where Hippocampe SA
     stockholders will exchange their stock for the common stock of ICHOR
     Corporation.  Because Hippocampe SA will be the continuing entity,
     this combination will be accounted for as a reverse purchase.

     During the first nine months of 2000 and the year ended December 31,
     1999, ICHOR Corporation had no significant operations other than the
     disposal of an unconsolidated subsidiary. Hippocampe SA is a company
     in the development stage which is involved in the research and
     development of human health products.  Hippocampe SA's main research
     efforts have been concentrated in the prevention and treatment of the
     AIDS virus.  All of Hippocampe SA's activities have been conducted in
     France.  The combined companies expect to continue the research and
     development activities.

     Consistent with the location of its activities, beginning January 1,
     1999, Hippocampe SA adopted the Euro (E) as its corporate currency.
     Accordingly, Hippocampe SA prepared its 2000 and 1999 historical
     financial statements in Euros.  Because Hippocampe SA is the
     continuing entity, these pro forma financial statements have been
     prepared using Euros.  The financial statements of ICHOR Corporation
     have been restated from U.S. dollars to Euros for each period
     presented.  The translation adjustments did not result in significant
     foreign currency gains or losses in the pro forma condensed combined
     statements of operations.

(2)  The unaudited pro forma condensed combined balance sheet as of
     September 30, 2000 and pro forma statements of operations for the
     nine month period ended September 30, 2000 and the year ended
     December 31, 1999 are based on historical financial statements of
     ICHOR Corporation and Hippocampe SA.  The unaudited pro forma
     condensed combined balance sheet as of September 30, 2000 gives
     effect to the proposed combination of ICHOR Corporation and
     Hippocampe SA as if it had occurred as of September 30, 2000.  The
     unaudited pro forma condensed combined statements of operations for
     the nine months ended September 30, 2000 and the year ended December
     31, 1999 have been prepared to illustrate the effects of the proposed
     combination of ICHOR Corporation and Hippocampe SA as if
     the combination occurred January 1, 1999.

     The pro forma condensed combined financial statements may not be
     indicative of the actual results of the acquisition.  The pro forma
     adjustments are based upon available information and certain
     assumptions that management believes are reasonable.  The
     accompanying unaudited pro forma condensed combined financial
     statements should be read in connection with the historical financial
     statements of ICHOR Corporation and Hippocampe SA.

<PAGE> 5

(3)  Pro forma adjustments include the effect of the following:

     -    ICHOR Corporation's redemption and conversion of all 564,706
          outstanding ICHOR Corporation preferred shares for cash of
          E2,476,000 and 3,247,060 shares of common stock;

     -    Issuance of 33,311,398 shares of ICHOR Corporation common stock
          and shares convertible into shares of common stock of ICHOR
          Corporation to the shareholders of Hippocampe SA; and

     -    Issuance of 2,017,854 shares of ICHOR Corporation common stock
          to MFC Merchant Bank SA, a related party, in settlement of
          transaction fees.  For purposes of the unaudited pro forma
          financial statements, the transaction fee is recorded at the
          quoted market price of ICHOR Corporation's common stock as at
          September 30, 2000 ($0.51 per share or E1,174,000).

(4)  Pro forma loss per share is adjusted to give effect to the issuance
     of shares to affect the acquisition, and the redemption and
     conversion of the preferred shares, as if these transactions had
     occurred on January 1, 1999.  Warrants and options are not included
     in the computation of diluted loss per share because the effect of
     the warrants and options would be anti-dilutive.<PAGE>

                                                                     EXHIBIT 4.1

                                 RESONATE INC.

                            STOCK OPTION AGREEMENT

     THIS STOCK OPTION AGREEMENT (the "Agreement") is made as of October 2,
1998, between Resonate Inc., a California corporation (the "Company"), and
Kenneth Schroeder (the "Optionee").

     1.   Grant of Option. The Company grants to the Optionee an option (the
          ---------------
"Option") to purchase 1,408,500 shares ("Shares") of the Company's common stock
("Common Stock") at an exercise price of $0.38 per Share (the "Exercise Price").
This Option is not intended to be an incentive stock option within the meaning
of Section 422 of the Internal Revenue Code of 1986, as amended (the "Code").

     2.   Exercise of Option. This Option shall be exercisable during its term
          ------------------
as follows:

          (a)  Right to Exercise. This Option may be exercised in whole or in
               -----------------
part at any time after the date of this Agreement, including as to Shares which
have not yet vested under the vesting schedule set forth in Section 2(b) below,
in accordance with the provisions of this Agreement and the Exercise Notice and
Restricted Stock Purchase Agreement attached hereto as Exhibit A.
                                                       ---------

          (b)  Vesting Schedule. The Shares issuable upon exercise of this
               ----------------
Option will be subject to repurchase by the Company at the original exercise
price and such repurchase right shall lapse in a series of installments measured
from August 1, 1998 (the "Vesting Commencement Date") as follows:

               (i)  One forty-eighth (1/48) of the Shares subject to this Option
shall vest and the Company's repurchase right with respect to thereto shall
terminate upon the expiration of each full month after the Vesting Commencement
Date, subject to the Optionee's continuing to be an employee (or a consultant if
Optionee changes from employee to consultant status with the Company's consent)
of the Company on such dates;

               (ii) In the event of (A) a merger, consolidation or other
reorganization of the Company with or into another corporation in which the
holders of the capital stock of the Company immediately prior to such
transaction hold less than fifty percent (50%) of the voting securities of the
surviving corporation after such transaction, or (B) the sale of all or
substantially all of the assets of the Company (any such event described in
clause (A) or (B), a "Change in Control"), fifty percent (50%) of the Shares
subject to this Option that are unvested as of the effective date of such Change
of Control shall vest and the Company's repurchase right with respect thereto
shall terminate immediately prior to the consummation of such Change of Control.
The remaining Shares subject to this Option that are unvested after a Change in
Control shall continue vesting at the same rate as prior to the Change of
Control. Notwithstanding the foregoing or anything else to the contrary in this
Agreement, a "Change of Control" shall not include any change of control of the
Company that results from an initial public offering of the Company's Common
Stock or any other financial investment in the Company.

                                       1
<PAGE>

               (iii) In the event that the surviving or acquiring corporation
(the "Surviving Corporation") in any Change of Control shall fail to offer to
Optionee, in Optionee's reasonable judgement, a position and title in the
Surviving Corporation equivalent to Optionee's position and title with the
Company immediately prior to such Change of Control (a "Constructive
Termination"), this Option shall fully vest as to all of the Shares, including
Shares as to which the Optionee would not otherwise be vested, and the Company's
repurchase right with respect thereto shall terminate upon such Constructive
Termination.

          (c)  Method of Exercise. This Option is exercisable by delivery of an
               ------------------
Exercise Notice and Restricted Stock Purchase Agreement in the form attached as
Exhibit A (the "Exercise Notice"), which shall state the election to exercise
---------
the Option, the number of Shares in respect of which the Option is being
exercised (the "Exercised Shares"), and such other representations and
agreements as may be required by the Company. The Exercise Notice shall be
completed by the Optionee and shall be delivered to Secretary of the Company.
The Exercise Notice shall be accompanied by payment of the aggregate Exercise
Price as to all Exercised Shares. This Option shall be deemed to be exercised
upon receipt by the Company of such fully executed Exercise Notice accompanied
by such aggregate Exercise Price.

     No Shares shall be issued pursuant to the exercise of this Option unless
such issuance and exercise complies with applicable laws.  Assuming such
compliance, for income tax purposes the Exercised Shares shall be considered
transferred to the Optionee on the date the Option is exercised with respect to
such Exercised Shares.

     3.   Term of Option. Subject to earlier termination as specified herein,
          --------------
this Option may be exercised until October 2, 2008, after which this Option
shall terminate.

     4.   Termination of Relationship. In the event of termination of optionee's
          ---------------------------
continuous status as an employee or consultant of the Company, this Option may
be exercised for a period of ninety (90) days after the date of such termination
(but in no event later than the expiration date of this Option as set forth in
Section 3 above) to the extent that the Option is vested on the date of such
termination. Optionee's continuous status as an employee or consultant shall not
be considered interrupted in the case of (i) any leave of absence approved by
the Company or (ii) transfers between locations of the Company or between the
Company, its parent, any subsidiary, or any successor. A leave of absence
approved by the Company shall include sick leave, military leave, or any other
personal leave approved by an authorized representative of the Company.
"Employee" means any person, including officers and directors, employed by the
Company or any parent or subsidiary of the Company. The payment of a director's
fee by the Company shall not be sufficient to constitute "employment" by the
Company. "Consultant" means any person who is engaged by the Company or any
parent or subsidiary to render consulting or advisory services and is
compensated for such services, and any director of the Company whether
compensated for such services or not. If the Company registers any class of any
equity security pursuant to the Securities Exchange Act or 1934, as amended, the
term Consultant shall thereafter not include directors who are not compensated
for their services or are paid only a director's fee by the Company. To the
extent that Optionee does not exercise this Option within the time specified
herein, the Option shall terminate.

                                       2
<PAGE>

     5.   Disability of Optionee. Notwithstanding the provisions of Section 4
          ----------------------
above, in the event of termination of Optionee's continuous status as an
employee or consultant of the Company as a result of his "disability" (within
the meaning of Section 22(e)(3) of the Code), Optionee may, but only within
twelve (12) months from the date of such termination (and in no event later than
the expiration date of the term of such Option as set forth in the Option
Agreement), exercise the Option to the extent otherwise entitled to exercise it
at the date of such termination. To the extent that Optionee was not entitled to
exercise the Option at the date of termination, or if Optionee does not exercise
such Option to the extent so entitled within the time specified herein, the
Option shall terminate.

     6.   Death of Optionee. In the event of termination of Optionee's
          -----------------
continuous status as an employee or consultant as a result of the death of
Optionee, the Option may be exercised at any time within twelve (12) months
following the date of death (but in no event later than the date of expiration
of the term of this Option as set forth in Section 3 above), by Optionee's
estate or by a person who acquired the right to exercise the Option by bequest
or inheritance, but only to the extent the Optionee could exercise the Option at
the date of death. If, after death, the Optionee's estate or a person who
acquired the right to exercise the Option by bequest or inheritance does not
exercise the Option within the time specified herein, the Option shall
terminate.

     7.   Optionee's Representations. In the event the Shares have not been
          --------------------------
registered under the Securities Act of 1933, as amended (the "Securities Act"),
at the time this Option is exercised, the Optionee shall, if required by the
Company, concurrently with the exercise of all or any portion of this Option,
deliver to the Company his Investment Representation Statement in the form
attached hereto as Exhibit B.
                   ---------

     8.   Lock-Up Period. Optionee hereby agrees that, if so requested by the
          --------------
Company or any representative of the underwriters (the "Managing Underwriter")
in connection with any registration of the offering of any securities of the
Company under the Securities Act, Optionee shall not sell or otherwise transfer
any Shares or other securities of the Company during the 180-day period (or such
other period as may be requested in writing by the Managing Underwriter and
agreed to in writing by the Company) (the "Market Standoff Period") following
the effective date of a registration statement of the Company filed under the
Securities Act. Such restriction shall apply only to the first registration
statement of the Company to become effective under the Securities Act that
includes securities to be sold on behalf of the Company to the public in an
underwritten public offering under the Securities Act. The Company may impose
stop-transfer instructions with respect to securities subject to the foregoing
restrictions until the end of such Market Standoff Period.

     9.   Method of Payment. Payment of the aggregate Exercise Price shall be by
          -----------------
any of the following, or a combination thereof, at the election of the Optionee:

          (a)  cash; or

          (b)  check; or

                                       3
<PAGE>

          (c)  surrender of other shares of Common Stock of the Company which
(i) in the case of Shares acquired pursuant to the exercise of a Company option,
have been owned by the Optionee for more than six (6) months on the date of
surrender, and (ii) have a fair market value (as determined by the Board of
Directors of the Company (the "Board") in good faith) ("Fair Market Value") on
the date of surrender equal to the aggregate Exercise Price of the Shares as to
which the Option is being exercised; or

          (d)  consideration received by the Company under a cashless exercise
program adopted by the Company; or

          (e)  delivery to the Company of a full recourse promissory note and
executed security agreement, in the forms attached hereto as Exhibit F and
                                                             ---------
Exhibit G respectively.
---------

     10.  Non-Transferability of Option. This Option may not be transferred in
          -----------------------------
any manner otherwise than by will or by the laws of descent or distribution and
may be exercised during the lifetime of Optionee only by the Optionee.  The
terms of this Agreement shall be binding upon the executors, administrators,
heirs, successors and assigns of the Optionee.

     11.  Adjustments upon Changes in Capitalization, Dissolution, Merger or
          ------------------------------------------------------------------
Asset Sale.
----------

          (a)  Changes in Capitalization. Subject to any required action by the
               -------------------------
shareholders of the Company, the number of shares of Common Stock covered by
this Option, as well as the price per share of Common Stock covered by this
Option, shall be proportionately adjusted for any increase or decrease in the
number of issued shares of Common Stock resulting from a stock split, reverse
stock split, stock dividend, combination or reclassification of the Common
Stock, or any other increase or decrease in the number of issued shares of
Common Stock effected without receipt of consideration by the Company; provided,
however, that conversion of any convertible securities of the Company shall not
be deemed to have been "effected without receipt of consideration." Such
adjustment shall be made by the Board, whose determination in that respect shall
be final, binding and conclusive. Except as expressly provided herein, no
issuance by the Company of shares of stock of any class, or securities
convertible into shares of stock of any class, shall affect, and no adjustment
by reason thereof shall be made with respect to, the number or price of Shares
of stock subject to this Option.

          (b)  Dissolution or Liquidation. In the event of the proposed
               --------------------------
dissolution or liquidation of the Company, the Board shall notify the Optionee
at least fifteen (15) days prior to such proposed action.  To the extent the
Option has not been previously exercised, the Option will terminate immediately
prior to the consummation of such proposed action.

          (c)  Merger. In the event of a merger of the Company with or into
               ------
another corporation, the Option shall be assumed or an equivalent option shall
be substituted by such successor corporation or a parent or subsidiary of such
successor corporation. If, in such event, the Option is not assumed or
substituted, the Option shall terminate as of the date of the closing of the
merger. For the purposes of this paragraph, the Option shall be considered
assumed if, following the merger, the option confers the right to purchase, for
each Share of stock subject to the Option immediately prior to the merger, the
consideration (whether stock, cash, or other securities or property) received in
the merger by holders of Common Stock for each Share held on the effective date
of the transaction (and if holders were offered a

                                       4
<PAGE>

choice of consideration, the type of consideration chosen by the holders of a
majority of the outstanding Shares); provided, however, that if such
consideration received in the merger was not solely common stock of the
successor corporation or its parent, the Board may, with the consent of the
successor corporation, provide for the consideration to be received upon the
exercise of the Option, for each Share of stock subject to the Option, to be
solely common stock of the successor corporation or its parent equal in fair
market value to the per share consideration received by holders of Common Stock
in the merger.

     12.  Tax Consequences. Some of the federal tax consequences relating to
          ----------------
the exercise and disposition of this Option, as of the date of this Option, are
set forth below.  THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND
REGULATIONS ARE SUBJECT TO CHANGE. THE OPTIONEE SHOULD CONSULT A TAX ADVISER
BEFORE EXERCISING THIS OPTION OR DISPOSING OF THE SHARES.

          (a)  Exercising the Option. The Optionee may incur regular federal
               ---------------------
income tax liability upon exercise of the Option. The Optionee will be treated
as having received compensation income (taxable at ordinary income tax rates)
equal to the excess, if any, of the Fair Market Value of the Exercised Shares on
the date of exercise over their aggregate Exercise Price. If the Optionee is an
employee or a former employee, the Company will be required to withhold from his
compensation or collect from Optionee and pay to the applicable taxing
authorities an amount in cash equal to a percentage of this compensation income
at the time of exercise, and may refuse to honor the exercise and refuse to
deliver Shares if such withholding amounts are not delivered at the time of
exercise.

          (b)  Disposition of Shares. If the Optionee holds Shares acquired upon
               ---------------------
exercise of the Option for at least one year, any gain realized on disposition
of the Shares will be treated as long-term capital gain for federal income tax
purposes.

          (c)  Section 83(b) Election for Unvested Shares Purchased Pursuant to
               ----------------------------------------------------------------
the Option. With respect to the exercise of the Option for unvested Shares, an
----------
election ("Election") may be filed by the Optionee with the Internal Revenue
Service within 30 days of the purchase of the Shares, electing pursuant to
        --------------
Section 83(b) of the Code to be taxed currently on any difference between the
purchase price of the Shares and their Fair Market Value on the date of
purchase. This will result in a recognition of taxable income to the Optionee on
the date of exercise, measured by the excess, if any, of the Fair Market Value
of the Shares at the time the Option is exercised over the purchase price for
the Shares. Absent such an election, taxable income will be measured and
recognized by Optionee at the time or times on which the Company's Repurchase
Option lapses. Optionee is strongly encouraged to seek the advice of his own tax
consultant(s) in connection with the purchase of the Shares and the advisability
of filing the Election under Section 83(b) and other similar tax provisions. A
form of Election under Section 83(b) is attached hereto as Exhibit E for
                                                           ---------
reference.

     13.  Entire Agreement; Governing Law. This Agreement constitutes the entire
          -------------------------------
agreement of the parties with respect to the subject matter hereof and
supersedes in its entirety all prior undertakings and agreements of the Company
and Optionee with respect to the subject matter hereof, and may not be modified
except by means of a writing signed by the Company and Optionee. This agreement
is governed by the internal substantive laws, but not the choice of law rules,
of California.

                                       5
<PAGE>

     14.  NO GUARANTEE OF CONTINUED SERVICE. OPTIONEE ACKNOWLEDGES AND AGREES
          ---------------------------------
THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED
ONLY BY CONTINUING TO PROVIDE SERVICES AS AN EMPLOYEE OR CONSULTANT OF THE
COMPANY AT THE WILL OF THE COMPANY (AND NOT THROUGH THE ACT OF BEING HIRED OR
BEING GRANTED AN OPTION). OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT THIS
AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET
FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED
ENGAGEMENT AS AN EMPLOYEE OR CONSULTANT FOR THE VESTING PERIOD, FOR ANY PERIOD,
OR AT ALL, AND SHALL NOT INTERFERE WITH OPTIONEE'S RIGHT OR THE COMPANY'S RIGHT
TO TERMINATE OPTIONEE'S RELATIONSHIP AS AN EMPLOYEE OR CONSULTANT AT ANY TIME,
WITH OR WITHOUT CAUSE.

                           [Signature Page Follows]

                                       6
<PAGE>

     By your signature and the signature of the Company's representative below,
you and the Company agree that this Option is granted under and governed by the
terms and conditions of this Agreement. Optionee has reviewed this Agreement in
its entirety, has had an opportunity to obtain the advice of counsel prior to
executing this Agreement and fully understands all provisions of this Agreement.
Optionee hereby agrees to accept as binding, conclusive and final all decisions
or interpretations of the Board upon any questions relating to this Agreement.
Optionee further agrees to notify the Company upon any change in the residence
address indicated below.

OPTIONEE:                                    RESONATE INC.

Signature:  /s/ Kenneth Schroeder            By:  /s/ Robert Greene
          ----------------------------           -----------------------------

Printed Name: Kenneth Schroeder              Printed Name: I. Robert Greene

                                             Title: Director

           [Signature Page of Resonate Inc. Stock Option Agreement]

                                       7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00019-of-00352.parquet"}]]